Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma
Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Gregor Manukian(Memorial Sloan Kettering Cancer Center), Stephanie Terzulli(Memorial Sloan Kettering Cancer Center), Philip O. Livingston(Memorial Sloan Kettering Cancer Center), Christina Gonzalez(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Sarah Powel(Memorial Sloan Kettering Cancer Center), Samuel Ejadi(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Manuel E. Engelhorn(Memorial Sloan Kettering Cancer Center), Jianda Yuan, Jian Wang(University College Cork), Yan Zhang(Memorial Sloan Kettering Cancer Center), Alan N. Houghton(Eastern Cooperative Oncology Group), Katherine S. Panageas(Mayo Clinic), Humilidad F. Gallardo(Memorial Sloan Kettering Cancer Center), Teresa Rasalan
Cited by 100
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k